Acadia Makes New Appointment
This article was originally published in Scrip
Acadia Pharmaceuticals Inc. has appointed Srdjan (Serge) Stankovic executive vice president, head of research and development. Most recently Stankovic was senior vice president of clinical development and medical affairs at Alkermes Plc. and prior to this he was senior vice president and head of global clinical development for Teva Pharmaceuticals. Stankovic also held executive positions in research and development at Forest Laboratories, Inc., Neurogen Corporation, Johnson and Johnson and UCB.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.